Cover Image
市場調查報告書

Bayer AG : 開發中產品分析

Bayer AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224545
出版日期 內容資訊 英文 250 Pages
訂單完成後即時交付
價格
Back to Top
Bayer AG : 開發中產品分析 Bayer AG - Product Pipeline Review - 2016
出版日期: 2016年04月30日 內容資訊: 英文 250 Pages
簡介

Bayer AG,是全球有數的醫療保健企業。投資控股公司也包括了其系列公司(Bayer HealthCare,Bayer CropScience,Bayer MaterialScience,Bayer Business Services,Bayer Technology Services and Currenta)。

本報告提供Bayer AG的治療用開發中產品之開發情形調查分析,提供您研究·開發概要,開發中產品概要,臨床實驗的各階段產品概要,藥物簡介,開發平台分析,企業資料等相關的系統性資訊。

目錄

Bayer AG概要

Bayer AG - 研究·開發概要

  • 主要治療領域

Bayer AG - 開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品 - 單獨療法
  • 開發中產品 - 聯合治療
  • 開發中產品 - 聯盟產品
  • 開發中產品 - 轉出授權產品

Bayer AG - 開發中產品的概要

  • 開發中產品 - 後期階段的開發中產品
  • 開發中產品 - 臨床實驗階段的開發中產品
  • 開發中產品 - 初期階段的開發中產品
  • 開發中產品 - 未確認階段的開發中產品

Bayer AG - 藥物簡介

  • aflibercept
  • BAY-818973
  • radium Ra 223 dichloride
  • rivaroxaban
  • (nifedipine + candesartan cilexetil)
  • amikacin sulfate
  • ciprofloxacin
  • copanlisib hydrochloride
  • damoctocog alfa pegol
  • dienogest
  • mapracorat
  • regorafenib
  • sorafenib tosylate
  • tedizolid phosphate
  • (anastrozole + levonorgestrel)
  • anetumab ravtansine
  • BAY-1067197
  • BAY-1142524
  • BAY-858501
  • finerenone
  • molidustat
  • refametinib
  • riociguat
  • roniciclib
  • vericiguat
  • vilaprisan
  • BAY sGCstim
  • BAY-1082439
  • BAY-1093884
  • BAY-1097761
  • BAY-1112054
  • BAY-1125976
  • BAY-1128688
  • BAY-1129980
  • BAY-1143269
  • BAY-1143572
  • BAY-1161909
  • BAY-1163877
  • BAY-1179470
  • BAY-1187982
  • BAY-1213790
  • BAY-1214784
  • BAY-1217389
  • BAY-1238097
  • Drug for Diabetic Foot Ulcer
  • Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma
  • Monoclonal Antibodies for Cancer
  • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis
  • Small Molecule to Inhibit Kinase for Inflammation and Cancer
  • Vaccine for Follicular Lymphoma
  • BAY sGCact
  • BAY-1001931
  • BAY-1024767
  • BAY-606583
  • Bay-846
  • BR-5489
  • Monoclonal Antibodies for Undisclosed Indication
  • Protein To Inhibit HER-2 Receptor for Breast Cancer
  • Protein to Inhibit PDGFR-Beta Receptor for Solid Tumors
  • Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder
  • Small Molecules to Inhibit Wnt Pathway for Cancer
  • ZK-191784
  • ZK-216348
  • Drugs for Endometriosis and Uterine Fibroids
  • Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers
  • Recombinant Protein for Solid Tumors
  • Small Molecule to Inhibit Epigenetic Target for Cancer
  • Small Molecules for Cancer
  • Immunotherapy for Cancer

Bayer AG - 開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Bayer AG - 開發中產品的最新趨勢

Bayer AG - 暫停的計劃

Bayer AG - 開發中止的開發中產品

  • 開發中止的開發中產品簡介

Bayer AG - 企業發表

Bayer AG - 總公司所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08042CDB

Summary

Global Markets Direct's, 'Bayer AG - Product Pipeline Review - 2016', provides an overview of the Bayer AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bayer AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG
  • The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bayer AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bayer AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Bayer AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bayer AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bayer AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bayer AG Snapshot
    • Bayer AG Overview
    • Key Information
    • Key Facts
  • Bayer AG - Research and Development Overview
    • Key Therapeutic Areas
  • Bayer AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Bayer AG - Pipeline Products Glance
  • Bayer AG - Late Stage Pipeline Products
  • Bayer AG - Clinical Stage Pipeline Products
  • Bayer AG - Early Stage Pipeline Products
  • Bayer AG - Unknown Stage Pipeline Products
  • Bayer AG - Drug Profiles
    • aflibercept
    • dienogest
    • Kovaltry
    • (candesartan cilexetil + nifedipine)
    • amikacin sulfate
    • ciprofloxacin hydrochloride
    • copanlisib hydrochloride
    • damoctocog alfa pegol
    • finerenone
    • nifurtimox
    • radium Ra 223 dichloride
    • regorafenib
    • rivaroxaban
    • tedizolid phosphate
    • (anastrozole + levonorgestrel)
    • anetumab ravtansine
    • BAY-1067197
    • BAY-1142524
    • molidustat
    • refametinib
    • riociguat
    • roniciclib
    • vericiguat
    • vilaprisan
    • sorafenib tosylate
    • BAY sGCstim
    • BAY-1082439
    • BAY-1093884
    • BAY-1112054
    • BAY-1125976
    • BAY-1128688
    • BAY-1129980
    • BAY-1143269
    • BAY-1143572
    • BAY-1161909
    • BAY-1163877
    • BAY-1179470
    • BAY-1187982
    • BAY-1213790
    • BAY-1214784
    • BAY-1217389
    • BAY-1251152
    • BAY-1862864
    • Drug for Diabetic Foot Ulcer
    • Monoclonal Antibodies for Oncology
    • Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers
    • Monoclonal Antibody for Undisclosed Indication
    • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis
    • Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders
    • Small Molecule to Inhibit Kinase for Inflammation and Oncology
    • BAY sGCact
    • BAY-1001931
    • BAY-1024767
    • BAY-1436032
    • BAY-606583
    • Bay-846
    • Immunotherapy for Oncology
    • Monoclonal Antibodies for Undisclosed Indication
    • Monoclonal Antibody to Inhibit CGEN-15001T for Oncology
    • Monoclonal Antibody to Inhibit CGEN-15022 for Oncology
    • Monocloncal Antibody Conjugate to Inhibit PDGFR-Beta Receptor for Solid Tumors
    • Recombinant Protein To Inhibit HER-2 Receptor for Breast Cancer
    • Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder
    • Small Molecules to Inhibit Mitogen Activated Protein Kinase Kinase for Oncology
    • Small Molecules to Inhibit MTH1 for Oncology
    • Small Molecules to Inhibit Wnt Pathway for Oncology
    • SMYD-2BAY02
    • ZK-191784
    • ZK-216348
    • Drugs for Endometriosis and Uterine Fibroids
    • Recombinant Protein for Solid Tumors
    • Small Molecule to Inhibit Epigenetic Target for Oncology
    • Small Molecules for Cardiovascular Disease
    • Small Molecules for Oncology
    • Small Molecules to Inhibit GLUT1 and GLUT2
    • Small Molecule for Undisclosed Indication
  • Bayer AG - Pipeline Analysis
    • Bayer AG - Pipeline Products by Target
    • Bayer AG - Pipeline Products by Route of Administration
    • Bayer AG - Pipeline Products by Molecule Type
    • Bayer AG - Pipeline Products by Mechanism of Action
  • Bayer AG - Recent Pipeline Updates
  • Bayer AG - Dormant Projects
  • Bayer AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Bayer AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bayer AG, Key Information
  • Bayer AG, Key Facts
  • Bayer AG - Pipeline by Indication, 2016
  • Bayer AG - Pipeline by Stage of Development, 2016
  • Bayer AG - Monotherapy Products in Pipeline, 2016
  • Bayer AG - Combination Treatment Modalities in Pipeline, 2016
  • Bayer AG - Partnered Products in Pipeline, 2016
  • Bayer AG - Partnered Products/ Combination Treatment Modalities, 2016
  • Bayer AG - Out-Licensed Products in Pipeline, 2016
  • Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bayer AG - Pre-Registration, 2016
  • Bayer AG - Phase III, 2016
  • Bayer AG - Phase II, 2016
  • Bayer AG - Phase I, 2016
  • Bayer AG - Preclinical, 2016
  • Bayer AG - Discovery, 2016
  • Bayer AG - Unknown, 2016
  • Bayer AG - Pipeline by Target, 2016
  • Bayer AG - Pipeline by Route of Administration, 2016
  • Bayer AG - Pipeline by Molecule Type, 2016
  • Bayer AG - Pipeline Products by Mechanism of Action, 2016
  • Bayer AG - Recent Pipeline Updates, 2016
  • Bayer AG - Dormant Developmental Projects,2016
  • Bayer AG - Discontinued Pipeline Products, 2016
  • Bayer AG, Subsidiaries

List of Figures

  • Bayer AG - Pipeline by Top 10 Indication, 2016
  • Bayer AG - Pipeline by Stage of Development, 2016
  • Bayer AG - Monotherapy Products in Pipeline, 2016
  • Bayer AG - Combination Treatment Modalities in Pipeline, 2016
  • Bayer AG - Partnered Products in Pipeline, 2016
  • Bayer AG - Out-Licensed Products in Pipeline, 2016
  • Bayer AG - Pipeline by Top 10 Target, 2016
  • Bayer AG - Pipeline by Top 10 Route of Administration, 2016
  • Bayer AG - Pipeline by Top 10 Molecule Type, 2016
  • Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top